REGN Aug 2024 945.000 put
| Previous Close | 20.60 |
| Open | 18.22 |
| Bid | 16.00 |
| Ask | 22.70 |
| Strike | 945.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 18.22 - 18.22 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 37 |
ZacksRegeneron (REGN) Announces Positive Data on Oncology Candidate
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
GlobeNewswirePromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors TARRYTOWN, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results
Simply Wall St.Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash Flow to Equity...
